* OBE THERAPY *
2000 - IDF
Évry
(near Paris)
www.obetherapy.com Discovery, Targets
(also, Discovery,, Drugs)
Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes
Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype
Clients: Pharmaceutical industry
iharosh@obetherapy.com
Age: 12 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO:
Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) | Turnover (M€) : n.a.
Total funding (M€) : 0.7
Last funding (M€) : 0.3
Focus : Cardiovasc
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2005 .06 | Partnering research agreement with Zambon (later acquired by Rottapharm), on low-molecular weight | R&D | [5 years] |
| 2002 .11 | Seed financing : 0.3 M€, by iXCore | SFIN | [2 years] |
| 2000 .01 | Company founded by Itzik Harosh, with public funds (Genopole 1er Jour, Anvar), amounting to 0.4 M€ | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
